Ayrton Drugs

Ayrton Drugs, formally Ayrton Drug Manufacturing Limited, was a Ghanaian pharmaceutical company established on September 24, 1965. The company operated a manufacturing facility in Tesano, a suburb of Accra, and became part of Ghana's domestic pharmaceutical manufacturing sector. Its portfolio covered several broad therapeutic categories, including medicines for cardiovascular conditions, nutritional and blood-related deficiencies, skin conditions, infections, parasitic diseases, pain, and inflammation. The company's product range included antihypertensive medicines, hematinics, dermatological preparations, antibiotics, dewormers, painkillers, and anti-inflammatory drugs. This breadth positioned Ayrton Drugs as a general pharmaceutical manufacturer rather than a narrowly focused specialist brand. Publicly available reference material does not provide sufficient detail to identify individual branded products, manufacturing capacity, export markets, or the company's principal executives. Ayrton Drugs was also connected to Ghana's public capital market. The business was listed on the Ghana Stock Exchange and included in the GSE All-Share Index. In February 2010, South African pharmaceutical company Adcock Ingram acquired a 66 percent stake in Ayrton Drugs. The transaction brought the Ghanaian manufacturer into the ownership structure of a larger regional pharmaceutical group, although the available reference material does not describe the subsequent operating arrangements in detail. By January 2020, Ayrton Drug Manufacturing Limited had merged with two other Ghanaian pharmaceutical companies, Dannex Limited and Starwin Products Limited. The combined business was listed on the Ghana Stock Exchange under the name DAS Pharma. This consolidation marked the end of Ayrton Drugs as a separately listed company and placed its manufacturing and commercial legacy within the merged Ghanaian pharmaceutical enterprise. Because the available source material is brief, details about the brand's continued use after the merger, product transfers, facilities, and current legal status are not established here.

Ayrton Drug Manufacturing Limited was established in Ghana on September 24, 1965. It developed as a domestic pharmaceutical manufacturing business and operated a factory in Tesano, an Accra suburb. The company manufactured medicines across a wide range of therapeutic areas, including hypertension, blood and nutritional deficiencies, dermatology, bacterial infections, parasitic infections, pain, and inflammation. Its reported portfolio consisted of antihypertensives, hematinics, dermatological preparations, antibiotics, dewormers, painkillers, and anti-inflammatory drugs. The available historical record does not identify the individual products associated with these categories, nor does it provide detailed information about research and development, production volumes, distribution infrastructure, or overseas operations. Ayrton Drugs became a publicly traded Ghanaian pharmaceutical company. Its shares were listed on the Ghana Stock Exchange and the company was included in the exchange's All-Share Index. A significant ownership change occurred in February 2010, when Adcock Ingram, a pharmaceutical company based in South Africa, acquired 66 percent of Ayrton Drugs. The transaction represented the entry of a regional pharmaceutical group into majority ownership of the Ghanaian manufacturer. Public reference material does not specify whether the Ayrton name was retained across all products or how the acquisition affected the Tesano operation. The company's independent corporate identity changed through a later consolidation. By January 2020, Ayrton Drug Manufacturing Limited had merged with Dannex Limited and Starwin Products Limited. The three businesses were combined and listed on the Ghana Stock Exchange as DAS Pharma. This merger ended Ayrton Drugs' separate position as a listed company and placed its corporate history within the new combined pharmaceutical group. The supplied reference material does not establish whether Ayrton Drugs continued as a consumer-facing product brand after the merger, whether its product registrations were transferred, or whether its factory remained in operation under the same name.

• 2020

  Merger into DAS Pharma

  [1]Ayrton Drugsen.wikipedia.org

  Ayrton Drugs merged with Dannex Limited and Starwin Products Limited, and the combined company was listed on the Ghana Stock Exchange as DAS Pharma.

• 2010

  Adcock Ingram acquired majority ownership

  [1]Ayrton Drugsen.wikipedia.org

  In February 2010, South African pharmaceutical company Adcock Ingram acquired a 66 percent shareholding in Ayrton Drugs.

• 1965

  Company established

  [1]Ayrton Drugsen.wikipedia.org

  Ayrton Drug Manufacturing Limited was established in Ghana on September 24, 1965.

A broad-based Ghanaian pharmaceutical manufacturer serving multiple therapeutic categories through locally produced medicines.

• Cardiovascular medicines

  Antihypertensive medicines

  Ayrton Drugs' reported portfolio included medicines used in the management of high blood pressure. The available source does not identify active ingredients, dosage forms, individual product names, or whether these products remained available after the company's merger into DAS Pharma.

• Blood and nutritional supplements

  Hematinics

  The company produced hematinic preparations, a category generally associated with supporting blood formation and addressing deficiencies such as iron deficiency. No specific Ayrton product names, formulations, or indications beyond the broad category are established by the supplied sources.

• Dermatology

  Dermatological preparations

  Dermatological preparations formed part of the company's general pharmaceutical portfolio. The source material does not provide details about the conditions treated, dosage forms, active ingredients, or whether these products were prescription or over-the-counter medicines.

• Anti-infective medicines

  Antibiotics

  Ayrton Drugs manufactured antibiotics for the treatment of bacterial infections. Available references mention the category but do not identify specific molecules, brands, formulations, regulatory approvals, or subsequent ownership of the products.

• Anti-parasitic medicines

  Dewormers

  The portfolio included deworming medicines used against intestinal or other parasitic infections. The historical source does not specify the compounds, target conditions, packaging, or distribution channels associated with these products.

• Analgesics and anti-inflammatory medicines

  Painkillers and anti-inflammatory medicines

  Ayrton Drugs also produced medicines for pain relief and inflammation. These were reported as broad product categories rather than named flagship brands, and the available sources do not establish their formulations or present-day availability.

• 2020

  Consolidation with Dannex and StarwinM&A

  Background

  Ayrton Drugs, Dannex Limited, and Starwin Products Limited were separate Ghanaian pharmaceutical businesses before the consolidation.

  Action taken

  The three companies merged and were listed on the Ghana Stock Exchange under the name DAS Pharma.

  Aftermath

  Ayrton Drugs ceased to be a separately listed company, while its corporate history became part of the merged DAS Pharma group.

  Source

• 2010

  Majority investment by Adcock IngramM&A

  Background

  Ayrton Drugs was an established Ghanaian pharmaceutical manufacturer and Ghana Stock Exchange-listed company when Adcock Ingram entered its ownership structure.

  Action taken

  Adcock Ingram acquired 66 percent of Ayrton Drug Manufacturing Limited in February 2010.

  Aftermath

  The acquisition made Adcock Ingram the majority shareholder. The supplied sources do not provide detailed information about operational, management, or product changes following the transaction.

  Acquired equity stake. 66% (February 2010)

  Source

• 2020

  Ayrton Drugs merged into DAS Pharma[1]Ayrton Drugsen.wikipedia.org

  M&A

  Ayrton Drug Manufacturing Limited merged with Dannex Limited and Starwin Products Limited, with the combined companies listed on the Ghana Stock Exchange as DAS Pharma.

• 2010

  Adcock Ingram acquired a majority stake in Ayrton Drugs[1]Ayrton Drugsen.wikipedia.org

  M&A

  South African pharmaceutical company Adcock Ingram acquired 66 percent of Ayrton Drug Manufacturing Limited in February 2010.

1. 1Ayrton Drugsen.wikipedia.org